SCHEMBL6738832

SCHEMBL6738832

O=C(O)C(=O)Nc1cc(Br)c(Oc2ccc(O)c(S(=O)(=O)c3ccc(F)cc3)c2)c(Br)c1

nearest known ligand 0.57

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
THRA P10827 3/20 0.43
THRB P10828 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1642407 0.88 THRA (0.58) THRATHRB
SCHEMBL1642056 0.88 HSD17B3 (0.44) THRATHRB
SCHEMBL1640543 0.84 THRA (0.51) THRATHRB
SCHEMBL14488975 0.83 THRB (0.50) THRATHRB
SCHEMBL6852998 0.81 THRB (0.57) THRATHRB
SCHEMBL6740076 0.80 THRA (0.44) THRATHRB
SCHEMBL6855048 0.80 THRB (0.57) THRATHRB
SCHEMBL6659411 0.79 POLB (0.47) THRATHRB
SCHEMBL7517348 0.79 THRA (0.60) THRATHRB
SCHEMBL6742192 0.79 THRA (0.52) THRATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6689896-B2 AMIC ACID DERIVATIVES NOVARTIS AG (CH) 2004-02-10 US claimed
JP-2002540189-A 2002-11-26 JP claimed
US-20020107390-A1 Thyromimetic organic compounds KUKKOLA PAIVI J (US) 2002-08-08 US claimed
WO-2002032408-A2 COMBINATIONS OF A THYROMIMETIC COMPOUND AND A STATIN NOVARTIS AG (CH) 2002-04-25 WO claimed
US-20020045751-A1 Thyromimetic organic compounds NOVARTIS AG (CH) 2002-04-18 US claimed
EP-1165502-A1 DIARYL DERIVATIVES AND THEIR USE AS MEDICAMENTS Novartis AG (CH) 2002-01-02 EP claimed
WO-2000058279-A1 DIARYL DERIVATIVES AND THEIR USE AS MEDICAMENTS NOVARTIS AG (CH) 2000-10-05 WO claimed
US-6790978-B2 4-HYDROXY-3-ARYLSULFONYL, 3-AMINOSULFONYL OR 3-AMINOCARBONYL-PHENOXYANILINOCARBONYL-OPTIONAL ALKYLENE-CARBOXYLIC ACID OR CARBONYL-5-TETRAZOLES NOVARTIS AG (CH) 2004-09-14 US disclosed
US-6689896-B2 AMIC ACID DERIVATIVES NOVARTIS AG (CH) 2004-02-10 US disclosed
US-6599942-B1 Method of lowering LDL cholesterol and Lipoprotein a levels in mammals using such compounds NOVARTIS AG (CH) 2003-07-29 US disclosed
US-20020107390-A1 Thyromimetic organic compounds KUKKOLA PAIVI J (US) 2002-08-08 US disclosed
US-20020045751-A1 Thyromimetic organic compounds NOVARTIS AG (CH) 2002-04-18 US disclosed
EP-1165502-A1 DIARYL DERIVATIVES AND THEIR USE AS MEDICAMENTS Novartis AG (CH) 2002-01-02 EP disclosed
WO-2000058279-A1 DIARYL DERIVATIVES AND THEIR USE AS MEDICAMENTS NOVARTIS AG (CH) 2000-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020045751-A1 Thyromimetic organic compounds TPO, THRA, LPO THRA 2/4885THRB 7/4885
US-20020107390-A1 Thyromimetic organic compounds TSHR, NR1H3, NR1H2 THRA 4/4885THRB 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.